Nu Skin Enterprises, Inc. filings document the company’s operating results, governance, executive leadership changes and financing arrangements. Recent 8-K reports include quarterly and annual financial-result releases, officer appointments and resignations, compensation arrangements, and material definitive agreements tied to amended credit facilities.
The company’s proxy materials provide annual meeting governance and executive-compensation disclosures, including board and compensation matters reported under Schedule 14A. Nu Skin’s regulatory record also reflects its capital structure and liquidity arrangements, including term loan and revolving credit facilities, alongside formal disclosures for its beauty and wellness operations, affiliate platform and Rhyz-related business activities.
Thomas Pisano R. reported acquisition or exercise transactions in this Form 4 filing.
NU SKIN ENTERPRISES, INC. director Thomas R. Pisano received a grant of Class A Common Stock as equity compensation. On June 1, 2026, he was awarded 26,643 shares at no purchase price, reflecting a stock-based award rather than an open-market buy. Following this grant, he directly holds 116,827 shares of Nu Skin Class A Common Stock, indicating the transaction increased his equity stake through a routine compensation-related award.
CAMPBELL DANIEL W reported acquisition or exercise transactions in this Form 4 filing.
NU SKIN ENTERPRISES, INC. director Daniel W. Campbell received a grant of 26,643 shares of Class A Common Stock at no cash cost, increasing his direct holdings to 65,859 shares. He also has indirect ownership of 10,010 shares through a limited liability company he and his spouse own and control, and 53,375 shares through an irrevocable family trust.
Nu Skin Enterprises, Inc. reported results from its 2026 Annual Meeting of Stockholders. Stockholders approved and adopted the Amended and Restated 2024 Omnibus Incentive Plan, which had previously been approved by the board and its Compensation and Human Capital Committee, subject to stockholder approval.
All nine director nominees, including Emma S. Battle and Ryan S. Napierski, were elected with over 33.5 million votes each in favor and 5,430,258 broker non-votes recorded for each seat. Stockholders gave advisory approval of the Company’s executive compensation with 33,111,458 votes for, 1,255,101 against, and 37,082 abstentions.
Approval of the Amended and Restated 2024 Omnibus Incentive Plan received 24,185,333 votes for, 10,177,825 against, and 40,483 abstentions. Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm, with 38,798,633 votes for, 970,082 against, and 65,184 abstentions.
Charles Schwab Investment Management Inc. files an Amendment to Schedule 13G reporting 4.45% ownership of Nu Skin Enterprises Class A Common Stock, representing 2,143,294 shares. The filing states sole voting and dispositive power over those 2,143,294 shares. The amendment is signed by Omar Aguilar on 05/13/2026.
Nu Skin Enterprises director Laura Nathanson reported an open-market sale of 2,676 shares of Class A Common Stock at $6.73 per share. After this transaction, she directly holds 30,473 shares. The sale represents a relatively small portion of her reported direct holdings.
Nu Skin Enterprises reported a Form 144 notice concerning proposed sales of Class A common stock executed through William Blair and Company LLC on 05/11/2026 on the NYSE. The filing lists 49,497,715 shares and prior compensatory dispositions of 3,811 and 11,330 Class A shares on 04/30/2024 and 05/29/2025, respectively.
Nu Skin Enterprises reported that Steven K. Hatchett decided to resign as Executive Vice President and Chief Product Officer due to family health circumstances, effective May 8, 2026. He will remain with the company as a strategic product advisor with an annual salary of $147,478.
The filing notes the company’s appreciation for his contributions as Chief Product Officer and confirms that its Chief Financial Officer, Chelsea K. Lantz, signed the report on behalf of the company.
Nu Skin Enterprises reported weaker results for the first quarter of 2026. Revenue fell 12.0% to $320.6 million from $364.5 million, as macroeconomic pressures and its ongoing business transformation reduced consumer spending and customer acquisition. Customers declined 14%, Paid Affiliates 8% and Sales Leaders 13% year over year across its core Nu Skin business.
Net income dropped to $1.8 million, or $0.04 per diluted share, compared with $107.5 million, or $2.14 per diluted share, a year earlier, when results benefited from a large gain on the sale of the Mavely business. The 2026 quarter also included $5.9 million of charges tied to winding down the BeautyBio business.
Gross margin slipped to 66.9%, while selling expenses rose to 34.3% of revenue as the company supported changes to its sales performance plan and the Prysm iO wellness platform rollout. Nu Skin ended the quarter with $200.4 million in cash and current investments, $225 million of total debt under a new credit agreement, and modestly negative operating cash flow.